Scinai Expands CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026
Event summary
- Scinai Immunotherapeutics will present at BIO-Europe Spring 2026 in Lisbon, March 23–25, following its acquisition of Recipharm Israel and strategic collaboration with Recipharm.
- The company's CDMO platform now includes a biologics site in Jerusalem and a small-molecule API site in Yavne, acquired from Recipharm.
- Scinai is seeking partnerships to advance its immunology pipeline, focusing on autoimmune and inflammatory diseases, particularly in dermatology.
The big picture
Scinai's expansion follows a broader industry trend of biopharmaceutical companies consolidating manufacturing capabilities to reduce execution risk and accelerate timelines. The strategic collaboration with Recipharm provides Scinai with access to additional capacity and technologies, positioning it as a unique partner for biotech and pharma companies seeking end-to-end development and commercial manufacturing solutions.
What we're watching
- Integration Success
- Whether Scinai can seamlessly integrate Recipharm Israel's operations and technologies into its existing platform.
- Pipeline Advancement
- The pace at which Scinai secures strategic partnerships to advance its immunology pipeline.
- Market Positioning
- How Scinai's expanded CDMO capabilities will position it against competitors in the biotech and pharmaceutical manufacturing space.
Related topics